表紙
市場調査レポート

ヒト血漿由来の治療薬市場の製品およびパイプライン分析

A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market

発行 Frost & Sullivan 商品コード 346561
出版日 ページ情報 英文 61 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
ヒト血漿由来の治療薬市場の製品およびパイプライン分析 A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market
出版日: 2015年12月08日 ページ情報: 英文 61 Pages
概要

世界のヒト血漿由来の治療薬市場は、疾患と治療法への意識向上などにより、需要拡大となる見込みです。新規の免疫グロブリン製品と治療法への意識向上が、市場の二桁成長を牽引しています。

当レポートでは、世界のヒト血漿由来の治療薬市場について調査し、上市済み製品およびパイプライン製品の競合動向、市場の牽引因子と課題などをまとめています。

第1章 エグゼクティブサマリー

第2章 調査方法と調査範囲

第3章 市場背景

  • 市場セグメンテーション
  • 市場予測

第4章 競合環境

  • 上市済み製品
  • パイプライン製品
  • 製品数
  • 治験動向

第5章 上市済み製品分析

  • アルブミン
  • 凝固因子
  • 免疫グロブリン

第6章 パイプライン製品分析

  • 承認済み
  • 第3相
  • 第2相
  • 第1相

第7章 製品ダッシュボード

  • ResusixTM, Entegrion, Inc.
  • CINRYZER, Shire
  • BIOSTATER, CSL Behring
  • Gammagard, Baxter

第8章 結論および提言

  • 結論および提言
  • 法的免責事項

第9章 付録

第10章 Frost & SUllicanストーリー

目次
Product Code: MAEC-52

Launch of Novel Immunoglobulin Products and Increasing Awareness of Therapeutic Options to Drive Double-digit Market Growth

The global human plasma-derived therapeutics market is expected to experience a surge in demand due to an increase in the awareness of diseases and therapeutic options. The plasma-derived therapeutics market is segmented into albumin, immunoglobulins, coagulation factors, and other haemotologicals. The segments are discussed with supporting information on clinical trial timelines and results and historical and projected launch timelines. The report also focuses on the competitive landscape of both marketed and pipeline products and provides the market drivers and challenges.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary
  • 2. Recent Market Developments
  • 3. Key M&As and Partnership Assessment
  • 4. Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

3. MARKET BACKGROUND

Market Background

  • 1. Market Background-Segmentation
  • 2. Market Background-Segmentation (continued)
  • 3. Market Background-Segmentation (continued)
  • 4. Market Segmentation
  • 5. Market Segmentation (continued)
  • 6. Market Forecasting

4. COMPETITIVE LANDSCAPE

Competitive Landscape

  • 1. Competitive Landscape-Human Plasma-derived Therapeutics: Marketed Products
  • 2. Competitive Landscape-Human Plasma-derived Therapeutics Market: Pipeline Products
  • 3. Competitive Landscape-Count of Marketed and Pipeline Products
  • 4. Competitive Landscape-Key Clinical Trials

5. MARKETED PRODUCT ANALYSIS

Marketed Product Analysis

  • 1. Marketed Products Synopsis-Albumin
  • 2. Marketed Products Synopsis-Other Haematologicals
  • 3. Marketed Products Synopsis-Other Haematologicals (continued)
  • 4. Marketed Products Synopsis-Coagulation Factors
  • 5. Marketed Products Synopsis-Coagulation Factors (continued)
  • 6. Marketed Products Synopsis-Coagulation Factors (continued)
  • 7. Marketed Products Synopsis-Coagulation Factors (continued)
  • 8. Marketed Products Synopsis-Immunoglobulins
  • 9. Marketed Products Synopsis-Immunoglobulins (continued)
  • 10. Marketed Products Synopsis-Immunoglobulins (continued)
  • 11. Marketed Products Synopsis-Immunoglobulins (continued)
  • 12. Marketed Products Synopsis-Immunoglobulins (continued)
  • 13. Marketed Products Synopsis-Immunoglobulins (continued)

6. PIPELINE PRODUCT ANALYSIS

Pipeline Product Analysis

  • 1. Pipeline Analysis-Approved
  • 2. Pipeline Analysis-Phase 3
  • 3. Pipeline Analysis-Phase 3 (continued)
  • 4. Pipeline Analysis-Phase 2
  • 5. Pipeline Analysis-Phase 1

7. PRODUCT DASHBOARD

Product Dashboard

  • 1. Product Dashboard-ResusixTM, Entegrion, Inc.
  • 2. Product Dashboard-CINRYZE® (new formulation), Shire
  • 3. Product Dashboard-BIOSTATE® (new formulation), CSL Behring
  • 4. Product Dashboard-Gammagard, Baxter

8. CONCLUSIONS AND RECOMMENDATIONS

Conclusions and Recommendations

  • 1. Conclusions and Recommendations
  • 2. Legal Disclaimer

9. APPENDIX

Appendix

  • 1. Plasma-Overview
  • 2. Plasma-Overview (continued)

10. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition-Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top